Abbreviations used in this paper: CAM, cell adhesion molecule; DRG, dorsal root ganglion; HEK, human embryonic kidney; HSPG, heparan sulfate proteoglycan; PNS, peripheral nervous system.

Introduction
============

The presence of voltage-gated Na^+^ channels at the nodes of Ranvier ensures fast saltatory propagation of action potentials in myelinated nerves. The accumulation of these channels at nodes is tightly regulated by the overlaying myelinating Schwann cells ([@bib40]; [@bib45]; [@bib46]). In the peripheral nervous system (PNS), the nodal axolemma is contacted by an ordered array of microvilli that project radially from the outer collar of two adjacent myelinating Schwann cells. These Schwann cell microvilli are embedded within a poorly defined filamentous matrix (i.e., the gap substance) that was referred to as the "cement disc" by Ranvier ([@bib27]). The nodal gap substance consists of proteoglycans and nonsulfated mucopolysaccharides, which contribute to the ability of a wide variety of metallic cations to label the nodes of Ranvier ([@bib56]). Proteoglycans that are present at peripheral nodes include versican ([@bib2]; [@bib37]), NG2 ([@bib34]), and syndecans ([@bib20]; [@bib37]), as well as hyaluronic acid and its binding protein hyaluronectin, which are associated with proteoglycans in the ECM ([@bib2]; [@bib13]). Several ECM and ECM-associated proteins are also enriched at PNS nodes, such as collagen α4(V) ([@bib37]), laminin α2β1γ1 and α5β1γ1 ([@bib39]), dystroglycan, and some members of the dystrophin--glycoprotein complex ([@bib39]; [@bib44]). Schwann cell--specific ablation of dystroglycan ([@bib44]), and to a lesser extent of laminin γ1 ([@bib39]), causes disruption of microvillar organization and reduction in nodal Na^+^ channel clustering, suggesting that the microvilli play a direct role in node assembly. This notion is further supported by observations demonstrating that Schwann cell microvillar processes align with nascent nodes ([@bib50]; [@bib36]).

At the nodal axolemma, Na^+^ channels associate with two cell adhesion molecules (CAMs), NrCAM and the 186-kD isoform of neurofascin ([@bib12]). Growing evidence suggests that during development, Na^+^ channels are recruited to clusters containing these axonodal CAMs that were first positioned by glial processes ([@bib26]; [@bib32]; [@bib11]; [@bib15]; [@bib48]; [@bib25]; [@bib47]). Neurofascin and NrCAM interact with gliomedin, which is concentrated at the Schwann cell microvilli ([@bib15]). During myelination, gliomedin accumulates at the edges of myelinating Schwann cells, where it is associated with early clusters of Na^+^ channels. In myelinating cultures, both the expression and correct localization of gliomedin are essential for node formation. Gliomedin is a type II transmembrane protein that is characterized by the presence of olfactomedin and collagen domains in its extracellular region, a domain organization shared by members of a specific subgroup of the olfactomedin proteins, termed colmedins ([@bib31]). In addition, gliomedin contains a putative α-helical, coiled-coil sequence at its juxtamembrane region, which serves as an oligomerization motif in collagenous transmembrane proteins ([@bib28]; [@bib16]). The olfactomedin domain of gliomedin was shown to mediate its interaction with neurofascin and NrCAM ([@bib15]). The aggregation of this domain using a secondary antibody was sufficient to induce nodelike clusters along the axons of isolated dorsal root ganglion (DRG) neurons. These observations led us to propose that the focal presentation of gliomedin to the axon during myelination causes the initial clustering of the axonodal CAMs into higher-order oligomers, which facilitates the recruitment of ankyrin G and Na^+^ channels ([@bib15]). We report that gliomedin is cleaved from the cell surface by a furin protease, and then assembles into high--molecular weight multimers and incorporates into the ECM by binding to HSPGs. We propose that these unique features endow gliomedin its ability to cluster the axonodal CAMs, thereby facilitating node formation.

Results
=======

Differential binding of gliomedin to DRG neurons and Schwann cells
------------------------------------------------------------------

We have previously shown that the OLF domain of gliomedin mediates it interaction with axonal neurofascin and NrCAM ([@bib15]). To examine the existence of additional ligands for gliomedin in peripheral nerves, we used a soluble Fc-fusion protein containing its extracellular domain but lacking its OLF domain (COL-Fc) in binding experiments on mixed DRG neurons/Schwann cell cultures ([Fig. 1, A and B](#fig1){ref-type="fig"}). Whereas OLF-Fc bound to neurons as expected, COL-Fc binding was detected to a subpopulation of Schwann cells that were aligned with axons. Binding experiments using cultures of rat Schwann cells, revealed that both COL-Fc ([Fig. 1 E](#fig1){ref-type="fig"}) and an Fc-fusion protein containing the entire extracellular domain of gliomedin (ECD-Fc; [Fig. 1 C](#fig1){ref-type="fig"}) labeled the cells, as well as areas between adjacent cells, suggesting that they interact with Schwann cell ECM. In contrast, OLF-Fc did not bind to Schwann cells ([Fig. 1 D](#fig1){ref-type="fig"}). To determine whether COL-Fc interacts with Schwann cell ECM, we have grown Schwann cells in the presence of ascorbate, which induces the formation of ECM fibrils and basal lamina--like structures ([@bib14]). In ascorbate-treated Schwann cells, binding of COL-Fc was detected to the cell surface, as well as to ECM deposits located between the cells ([Fig. 1 F](#fig1){ref-type="fig"}). COL-Fc still bound these ECM deposits in cultures that were pretreated with ammonium hydroxide and Triton X-100, a procedure that completely removed the cells from the slide but left the ECM fibrils intact ([Fig. 1 G](#fig1){ref-type="fig"}). To determine whether the interaction of COL-Fc with the ECM was specific to Schwann cells, we examined whether it binds astrocytes, which are known to accumulate similar ECM structures in culture ([@bib3]). As depicted in [Fig. 1](#fig1){ref-type="fig"} (H and I), COL-Fc bound to the cell surface of astrocytes, but it did not bind to cell-free areas or to cultures pretreated with ammonium hydroxide and Triton X-100. These results demonstrate that the extracellular region of gliomedin contains distinct domains that mediate its interaction with both neurons and Schwann cells. They further suggest the existence of a novel glial ligand for gliomedin embedded within the Schwann cell ECM.

![**Distinct domains of gliomedin mediate its interaction with neurons and Schwann cell ECM.** The domain organization of gliomedin and the Fc-fusion proteins used in binding experiments are depicted at the top. TM, transmembrane domain; cc, coiled-coil; NTR, N-terminal region; COL, interrupted collagen repeats; OLF, olfactomedin domain. (A and B) Gliomedin interacts with both neurons and Schwann cells. Binding of OLF-Fc or COL-Fc to dissociated embryonic DRG cultures; Fc binding is shown in red, neurons were labeled with an antibody to βIII tubulin (Tuj1; green), and the nuclei of both neurons and Schwann cells were labeled with DAPI (blue). Note the binding of COL-Fc to a group of Schwann cells that are aligned with axons (arrowheads). At this stage of the culture, only a few neurons express neurofascin and bound OLF-Fc. (C--E) Interaction of gliomedin with Schwann cells. Binding ECD-Fc (containing the entire extracellular domain of gliomedin), OLF-Fc, or COL-Fc (all in red) to cultured rat Schwann cells, as indicated. Cells were labeled with Alexa Fluor 488 phalloidin to detect actin (Act; green), and the nuclei were labeled with DAPI (blue). Note the robust binding of ECD-Fc and COL-Fc, but not of OLF-Fc in between the cells (arrowheads). (F) Interaction of gliomedin with Schwann cell ECM. Binding of COL-Fc (red) to ascorbic acid--treated culture of rat Schwann cells. Actin was labeled with Alexa Fluor 488 phalloidin (Act; green) and the nuclei were labeled with DAPI (blue). COL-Fc bound to the cell surface, as well as to ECM deposits located between the cells. (G) Before binding of COL-Fc and labeling as in C, the slides were washed using ammonium hydroxide and Triton X-100 to remove the cells. COL-Fc bound to ECM components that were still present on the slide after removal of the cells. (H and I) The same experiment was performed using cultured astrocytes. In contrast to Schwann cells, COL-Fc binding to astrocytes was only detected on the cell surface and was eliminated after removal of the cells. Bars: (C--E) 30 μm; (F--I) 15 μm.](jcb1770551f01){#fig1}

Gliomedin is found in both transmembrane and secreted forms
-----------------------------------------------------------

The domain organization of gliomedin is reminiscent of transmembrane collagens, all of which are type II transmembrane proteins that are cleaved from the cell membrane by furin-type endoprotease ([@bib16]). Hence, the ability of gliomedin to bind ECM deposits that are not cell surface--associated raises the question of whether it is secreted from Schwann cells. To examine this possibility, we immunoprecipitated gliomedin from cell lysates and media of cultured Schwann cells using an antibody to the cytoplasmic tail (Ab836), or an antibody directed to the olfactomedin domain (Ab320). As a control, we used human embryonic kidney (HEK)-293 cells that were transfected with a C-terminal, myc-tagged, full-length gliomedin cDNA. Immunoblots were then performed using an antibody to myc tag or an antibody that recognizes a short peptide sequence between the collagen and the olfactomedin domain (Ab720; recognition sites of the various antibodies is schematically depicted in [Fig. 2 C](#fig2){ref-type="fig"}). Ab836 and Ab320 immunoprecipitated an 89-kD protein from the lysates of Schwann cells that correspond to the transmembrane form of gliomedin ([Fig. 2 A](#fig2){ref-type="fig"}, middle). In transfected HEK-293 cells, the transmembrane form of gliomedin appeared as a doublet consisting of the 89-kD and a weaker ∼92-kD band. In addition, Ab320 specifically precipitated a 91-kD protein from the medium of both cell types and a 45-kD protein from the transfected HEK-293 cells. The 45-kD protein was also detected in the medium of Schwann cells that were maintained in culture for longer periods of time ([Fig. 2 A](#fig2){ref-type="fig"}, right). Treatment of gliomedin immunocomplexes with N-glycosidase revealed that the core protein of the secreted form is smaller by ∼11 kD than the transmembrane protein (62 vs. 73 kD; [Fig. 2 B](#fig2){ref-type="fig"}). This analysis demonstrates that gliomedin is secreted from Schwann cells as a major 91-kD and a minor 45-kD protein.

![**Gliomedin is a secreted protein generated by proteolysis.** (A) Secretion of gliomedin by cultured cells. Media conditioned by cultured Schwann cells or HEK-293 cells transfected with a full-length, myc-tagged gliomedin cDNA were subjected to immunoprecipitation using antibodies that recognize the N- (Ab836) or C-terminal (Ab320) region of gliomedin (the region each antibody recognizes is shown in B). Western blotting was done using an antibody that recognizes a peptide located between the COL and OLF domains (MAb94) or to myc tag, as indicated. The location of molecular weight marker is shown on the right. (B) Glycosylation of gliomedin. Gliomedin was immunoprecipitated with Ab320 from cell lysate or the medium of HEK-293 cells transfected with a full-length, myc-tagged gliomedin cDNA. Washed immunocomplexes were incubated with N-Glycosidase F (PNGase) as indicated, separated on a 12% SDS gel, and immunoblotted with an antibody to myc tag. Note that the core protein of the secreted gliomedin form (62 kD) is smaller by ∼11 kD than the transmembrane form found in the cell lysate (73 kD). (C) Identification of cleavage sites in gliomedin. (right) Western blot analysis of protein-A--purified material from medium (CM) of HEK-293 cells expressing a C-terminal Fc-fusion protein of a full-length gliomedin, using an antibody to human Fc; the presence of the Fc adds 30 kD. A schematic presentation of the two gliomedin fragments isolated is depicted on the left, together with the domain organization of the protein, the location of the cleavage sites (arrowheads), and the regions recognized by the different antibodies. The second proteolytic cleavage site, which is located just N-terminal to the OLF domain (PNDD), was identified by N-terminal sequencing, whereas the first furin site (RNKR) within the NTR was identified by mutagenesis. The locations of R91 and R94 are labeled with asterisks. Color frames mark the different domains (gray, transmembrane; purple, coiled coil; blue, collagen; red, olfactomedin). (D) Secretion of the extracellular domain of gliomedin requires cleavage at a furin site. The media or cell lysates of HEK293 expressing a full-length gliomedin (WT) or a mutant form in which arginines 91 and 94 were replaced with glycine and alanine, respectively (R91G94A), were analyzed by immunoprecipitation using Ab320 and immunoblotting with MAb94 as indicated. Note the decreased amount of gliomedin present in the media and the increase in the amount of the 82-kD transmembrane form (upper band in the doublet) in the cell lysate. (E) Only a secreted gliomedin is detected at the nodes of Ranvier. Teased rat sciatic nerves were immunolabeled using the different antibodies to gliomedin (red) and an antibody to Caspr (green), as indicated. Bar, 5 μm.](jcb1770551f02){#fig2}

To directly determine the cleavage sites in gliomedin, we used an Fc-fusion protein in which the Fc region was fused to the C-terminal region of the full-length gliomedin. The rationale behind this approach was that because gliomedin is a type II transmembrane protein, cleavage of the protein should result in the release of an Fc-tagged protein to the medium, which could be purified using protein A agarose. Two distinct bands of ∼116 and 80 kD were purified from the medium of HEK-293 expressing this construct and were subjected to N-terminal amino acid sequencing ([Fig. 2 C](#fig2){ref-type="fig"}). The N-terminal sequence of the lower band was identified as DDTLV, which corresponds to position 278 of rat gliomedin (NP_852047), which is located just before the beginning of the olfactomedin domain. Despite several attempts, we were unable to obtain the N-terminal sequence of the larger band. Analyzing the amino acid sequence of gliomedin between the transmembrane and the collagen domains (position 38--138) for functional sites using the Eukaryotic Linear Motif server (<http://elm.eu.org/>; [@bib41]), revealed the presence of a putative furin cleavage site (RNKR) at position 91--94. To determine whether this proteolytic site is important to the processing of gliomedin, we have constructed a mutant of the full-length gliomedin by replacing arginine at position 91 with glycine and arginine at position 94 with alanine (R91G94A). This mutant was transfected to HEK-293 cells, and the medium of these cells was analyzed 2 d later for the presence of gliomedin ([Fig. 2 D](#fig2){ref-type="fig"}). Mutating these arginines caused a marked reduction in the secretion of gliomedin to the medium, and was accompanied by an accumulation of the 92-kD transmembrane form in the cells. These results indicate that proteolytic cleavage of the mature 92-kD form by a furin-like enzyme mediates the shedding of the extracellular domain of gliomedin from the cell surface. In addition, and less frequently, another cleavage of the molecule at position 278 may occur, which separates the olfactomedin domain from the collagen triplex. Immunolabeling of teased rat sciatic nerves demonstrated a nodal staining of gliomedin using Ab320 and Ab720, but not when Ab836 was used (Ab836 does recognize gliomedin in Schwann cells; see [Fig. 6 L](#fig6){ref-type="fig"}), demonstrating that only the extracellular domain of gliomedin was detected at the nodes ([Fig. 2 E](#fig2){ref-type="fig"}). Furthermore, the transmembrane form of gliomedin was not detected at nascent nodes during their development at sites that were labeled with the antibodies to the extracellular domain (unpublished data). Thus, we concluded that the main form of gliomedin found at the nodes of Ranvier is the cleaved form that contains the entire extracellular domain, including its collagen and olfactomedin domains.

Ascorbic acid induces the multimerization of gliomedin
------------------------------------------------------

The presence of a protease-resistant collagen domain in gliomedin indicates that it may assemble into homotrimers or higher-order multimers after cleavage from the cell surface. To test this possibility, we immunoprecipitated gliomedin from Schwann cells that were grown in the absence or presence of ascorbate, which stimulates the deposition of fibrillar collagen by Schwann cells ([@bib10]). Under reducing conditions, only a monomeric form of gliomedin with an apparent molecular weight of 89 kD protein was detected in both untreated and ascorbic acid--treated cells ([Fig. 3 A](#fig3){ref-type="fig"}). However, in the presence of a chemical cross-linker (BS^3^), only high-molecular weight multimers of gliomedin were detected in ascorbic acid--treated cells ([Fig. 3 A](#fig3){ref-type="fig"}). These multimers were detected using an antibody to the extracellular, but not to the cytoplasmic tail, of gliomedin ([Fig. 3 B](#fig3){ref-type="fig"}, right). Collectively, these results demonstrate that ascorbate treatment of Schwann cells induced the secretion, cleavage, and oligomerization of gliomedin.

![**Oligomerization and self-association of secreted gliomedin.** (A) Ascorbic acid induced the formation of gliomedin multimers. Schwann cells grown in the absence (−) or presence (+) of ascorbic acid were washed and incubated with the BS^3^ cross-linker, as indicated. Cell lysates were made and used to immunoprecipitate gliomedin with an antibody to the OLF domain, followed by immunoblotting using MAb94. The location of gliomedin monomers (*Mono*) and high-molecular weight multimers (*HMW*) is indicated with arrows. (B) Lysates of BS^3^-treated Schwann cells grown in the absence (−) or presence (+) of ascorbic acid were subjected to immunoprecipitation using an antibody directed to the OLF domain, followed by immunoblot analysis using an antibody directed to the cytoplasmic domain (836; left); the membrane was reblotted with MAb94 (right). Gliomedin multimers were detected with Ab720, but not with Ab836. (C) Domain organization of gliomedin and the various Fc-fusion proteins used in D and E. TM, transmembrane domain; cc, coiled coil; NTR, N-terminal region; COL, interrupted collagen repeats; OLF, olfactomedin domain; ECDdCC, ECD lacking the coiled-coil domain; ECDdNTR, ECD lacking the NTR; Fc, constant region of human IgG. (D) Self-association of gliomedin. The indicated Fc-fusion proteins were used to precipitate proteins from lysates of HEK-293 cells expressing a myc-tagged gliomedin (Gliomedin) or a myc-tag PSD93, followed by immunoblotting with an antibody to myc tag. Note the reduction in the ability of ECDdCC and ECDdNTR to pull down myc-gliomedin. (E) Binding of the olfactomedin domain of gliomedin to neurofascin requires its preclustering. The indicated Fc-fusion proteins were incubated either directly (Nonclustered) or after preincubation with an anti-Fc antibody (Preclustered) with COS7 cells expressing neurofascin 186 (NF186). Bound Fc was detected using Cy3-conjugated antibody to human Fc (red), and the expression of NF186 was determined using a specific antibody (green). The location of molecular weight markers in kilodaltons is shown in A, B, and D. Bar, 30 μm.](jcb1770551f03){#fig3}

Multimerization of gliomedin is required for its interaction with axonodal CAMs
-------------------------------------------------------------------------------

To determine which region in gliomedin mediates its self-association, we examined the ability of purified Fc-fusion proteins containing its entire extracellular domain (ECD-Fc), olfactomedin domain (OLF-Fc), ECD lacking the olfactomedin domain (COL-Fc), ECD lacking the coiled-coil domain (ECDdCC-Fc), and ECD lacking its N-terminal linker region (ECDdNTR) to precipitate a full-length myc-tagged gliomedin from transfected HEK-293 cells ([Fig. 3 C](#fig3){ref-type="fig"}). Similar amounts of the Fc-fusion proteins were used, as detected by immunoblotting with an antibody to human Fc (unpublished data). As an additional control, we used HEK-293 cells expressing a myc-tagged PSD93. Whereas ECD-Fc and COL-Fc specifically pulled-down gliomedin, ECDdCC-Fc was less efficient (estimated 50% reduction), and only a weak signal was obtained using ECDdNTR-Fc. OLF-Fc was unable to recognize and precipitate gliomedin ([Fig. 3 D](#fig3){ref-type="fig"}). To further explore the functional significance of these observations, we examined whether self-association of gliomedin is required for its interaction with neurofascin and NrCAM. To this end, COS7 cells expressing neurofascin (NF186) were incubated with the different Fc-fusion proteins as either dimers (i.e., caused by the presence of the Fc) or as multimers by preclustering them with a secondary antibody to human Fc ([Fig. 3 E](#fig3){ref-type="fig"}). It was found that, in contrast to ECD-Fc and ECDdCC-Fc, which bound to NF186-expressing cells without preclustering, only multimeric forms of ECDdNTR-Fc and OLF-Fc were able to recognize neurofascin. Similar results were obtained using DRG neurons (unpublished data). Thus, although the olfactomedin domain of gliomedin mediates its direct interaction with the axonodal CAMs ([@bib15]), multimerization of the extracellular domain of gliomedin, which is conferred by other sequences present at the N-terminal region of the molecule, is essential for this interaction to take place.

Secreted gliomedin multimers are incorporated into the Schwann cell ECM
-----------------------------------------------------------------------

The observation that a secreted extracellular domain of gliomedin can bind to Schwann cells, has prompted us to examine whether the endogenous gliomedin is incorporated into the Schwann cell ECM. Thus, we immunolabeled cultured rat Schwann cells with antibodies to gliomedin, together with antibodies to the known components of Schwann cell ECM, laminin ([Fig. 4, E--G](#fig4){ref-type="fig"}), and the α4(V) collagen chain ([Fig. 4, A--C](#fig4){ref-type="fig"}). In Schwann cells grown in the absence of ascorbic acid, gliomedin was mostly present on the cell surface, whereas α4(V) immunoreactivity was detected on the cell surface and between the cells. Growing the cells in the presence of ascorbic acid for 48 h resulted in a dramatic incorporation of gliomedin into fibrillar ECM deposits, where it was found to be colocalized with α4(V), mainly in the larger fibrils ([Fig. 4, A--C](#fig4){ref-type="fig"}). Similar results were obtained using antibodies to perlecan and the α1(V) chain of collagen (unpublished data). Previous studies have shown that after ascorbic acid treatment, α4(V) incorporates into detergent-insoluble ECM material ([@bib10]). To examine whether gliomedin was incorporated into similar structures, we immunoprecipitated gliomedin from ascorbic acid--treated Schwann cells that were extracted with a modified RIPA buffer, or with a RIPA buffer containing 1% SDS ([Fig. 4 D](#fig4){ref-type="fig"}). Cells grown in the absence of ascorbic acid were used as a control. Western blot analysis of these immunoprecipitants showed that the inclusion of SDS significantly increased the amount of gliomedin detected in the lysates of ascorbic acid--treated cells, but had no effect on the immunorecovery of gliomedin from untreated cells. A large amount of gliomedin was detected in the insoluble material obtained after the extraction of ascorbic acid--treated cells, with the modified RIPA buffer lacking SDS ([Fig. 4 D](#fig4){ref-type="fig"}, bottom), whereas the addition of SDS to the lysis buffer significantly reduced the amount of gliomedin in the insoluble pellet.

![**Gliomedin is incorporated into Schwann cells ECM.** (A--C) Association of gliomedin with the ECM is induced by ascorbic acid. Rat Schwann cells were grown in the absence (DME) or the presence (Ascorbate) of ascorbic acid and immunolabeled with antibodies to gliomedin (A; red) and collagen α4(V) (B; green). The merged image is shown on the right (C). (D) Ascorbic acid increases the insolubility of gliomedin. Schwann cells grown in DME or in the presence of ascorbic acid were lysed in a modified RIPA buffer (−) or RIPA buffer containing 1% SDS (+) as indicated. Cell lysates were cleared by centrifugation, and the insoluble pellet was resuspended in sample buffer (Pellet). Gliomedin was immunoprecipitated from the supernatant (Lysate) using an antibody to the OLF domain (320). The isolated immunocomplexes and the insoluble pellets were resolved on an SDS gel and immunoblotted with MAb94. The location of a 100-kD molecular weight marker is shown in each gel. (E--G) Incorporation of gliomedin into ECM fibrils. Schwann cells grown in the presence of ascorbic acid to induce ECM formation were washed with PBS, or with PBS containing ammonium hydroxide and Triton X-100 to remove the cells before immunolabeling with antibodies to gliomedin (E; red) and laminin (F; green). The merged image is shown in G. Bars, 30 μm.](jcb1770551f04){#fig4}

To ascertain that gliomedin was incorporated into Schwann cell ECM, cultures of Schwann cells grown in the presence of ascorbic acid were washed with ammonium hydroxide and Triton X-100 to remove the cells, and then immunolabeled using antibodies to gliomedin and laminin ([Fig. 4, E--G](#fig4){ref-type="fig"}). In nontreated cultures, gliomedin immunoreactivity was detected on the surface of the cells, as well as in fibrillar structures that were also labeled for laminin (top). After cell removal, most of the gliomedin immunoreactivity was associated with laminin-positive fibrils, further supporting the conclusion that it is incorporated into the ECM network. Notably, the extracellular domain of neurofascin (NF155-Fc; NF155 and NF186 are used interchangeably, as they both bind gliomedin) bound to ECM deposits that remained after Schwann cell removal, demonstrating that this axonodal CAM still recognizes the ECM-incorporated multimers of gliomedin ([Fig. 5 A](#fig5){ref-type="fig"}). The binding of Fc-fusion proteins containing the extracellular domain of Necl1/SynCAM3, which is a CAM that interacts with Schwann cells, was abolished after the removal of the cells ([Fig. 5 C](#fig5){ref-type="fig"}), demonstrating that the ammonium hydroxide and Triton X-100 wash used did not create nonspecific Fc-binding sites on the slides. Finally, similar experiments done using rat astrocytes revealed that although these cells secrete large quantities of gliomedin to their culture medium (not depicted), NF155-Fc binding was only detected on the cell surface ([Fig. 5 B](#fig5){ref-type="fig"}), indicating that gliomedin was not incorporated into the ECM produced by these cells. This conclusion is further supported by the observation that the extracellular domain of gliomedin did not bind astrocyte ECM, which suggests that Schwann cells produce a specific ECM ligand for gliomedin ([Fig. 1 I](#fig1){ref-type="fig"}). Collectively, these results demonstrate that upon ascorbic acid treatment, gliomedin is secreted from the cells and forms high-molecular weight multimers that are entrapped in the Schwann cell ECM.

![**Binding of neurofascin to ECM-bound gliomedin.** Ascorbic acid--treated cultures of rat Schwann cells (A and C) or astrocytes (B) were washed with PBS (top) or ammonium hydroxide and Triton X-100 to remove the cells (bottom). Slides were incubated with an Fc-fusion protein containing the extracellular domain of neurofascin (A and B; NF155-Fc), or the extracellular domain of Nectin-like protein 1 (C; Necl1-Fc) coupled to Cy3-conjugated anti--human Fc antibody (red). Unbound material was washed away, and the cells were fixed and stained with Alexa Fluor 488-phalloidin to detect actin (green) and with DAPI to visualize nuclei (blue). Bar, 30 μm.](jcb1770551f05){#fig5}

Association of gliomedin with Schwann cell ECM is mediated by heparan sulfate proteoglycans
-------------------------------------------------------------------------------------------

At the perinodal space, gliomedin is concentrated on the Schwann cell microvilli ([@bib15]), which are embedded in the proteoglycan-rich perinodal matrix. To examine whether the association of gliomedin with Schwann cells ECM is mediated by heparan sulfate proteoglycans (HSPGs), we used NF155-Fc as a specific affinity reagent to detect gliomedin in ascorbate-treated Schwann cells that were incubated with heparin. As depicted in [Fig. 6 A](#fig6){ref-type="fig"}, in the absence of heparin, gliomedin was present on both the cell surface and in ECM deposits between adjacent cells. In cultures incubated for 30 min with heparin, gliomedin was released from the ECM and was only present on the cell surface ([Fig. 6 B](#fig6){ref-type="fig"}). The removal of gliomedin from Schwann cell ECM by heparin was even clearer using cultures that were prewashed with ammonium hydroxide and Triton X-100 to remove the cells ([Fig. 6, C and D](#fig6){ref-type="fig"}). In contrast to gliomedin, heparin had no effect on the distribution of α4(V) ([Fig. 6, E--J](#fig6){ref-type="fig"}) or other Schwann cell ECM components, such as laminin (unpublished data). Immunolabeling with an antibody to the cytoplasmic domain of gliomedin indicated that, in heparin-treated Schwann cells, NF155-Fc bound to the transmembrane form of gliomedin present on the cell surface ([Fig. 6, K--M](#fig6){ref-type="fig"}).

![**Removal of gliomedin from Schwann cell ECM by heparin.** (A and B) Binding of Fc-fusion protein containing the extracellular domain of neurofascin (NF155-Fc; red) to ascorbic acid--treated rat Schwann cells (A), or after incubation of the ascorbic acid-treated cells with heparin (B). (C and D) NF155-Fc still bound to gliomedin that is present in the ECM after removing the cells with ammonium hydroxide and Triton X-100 (C), but not after prior incubation of the slides with heparin (D). Nuclei are labeled with DAPI (blue). (E--J) Heparin treatment removed gliomedin, but not α4(V), from the ECM. NF155-Fc binding (red) to ascorbic acid--treated Schwann cells, without (E) or with (H) preincubation of the cells with heparin. Cells were then fixed and immunolabeled with an antibody to α4(V) collagen (F and I; green), and the merged images are shown in G and J. (K--M) The transmembrane form of gliomedin mediates binding of NF155-Fc to Schwann cells after heparin treatment. NF155-Fc binding to ascorbic acid and heparin--treated rat Schwann cells (K; red). Cells were then fixed, permeabilized, and immunolabeled with an antibody 836 directed to the intracellular domain of gliomedin (L; green). Schwann cells nuclei were labeled with DAPI (blue). The merged image is shown in M. Bars: (A--J) 30 μm; (K--M) 15 μm.](jcb1770551f06){#fig6}

The efficient removal of secreted gliomedin by heparin indicates that its association with Schwann cells ECM requires HSPGs. To establish whether gliomedin interacts with HSPGs, we tested the effect of heparin on the binding of its extracellular domain (ECD-Fc) to Schwann cells. As depicted in [Fig. 7, A--D](#fig7){ref-type="fig"}, heparin completely inhibited the binding of ECD-Fc, suggesting that gliomedin binds to glycosaminoglycan side chains of HSPGs expressed by Schwann cells. To examine whether gliomedin binds directly to heparin, we incubated the Fc-fusion proteins containing the different domains of gliomedin with heparin-Sepharose and detected the bound material by immunoblotting with an antibody to human Fc ([Fig. 7 E](#fig7){ref-type="fig"}). As control, we used protein A beads, which precipitated all of the Fc-fusions tested. The extracellular domain of gliomedin (ECD), as well as an ECD lacking the olfactomedin domain (COL), the coiled-coil domain (ECDdCC), or its N-terminal linker region (ECDdNTR), bound to the heparin affinity matrix. In contrast, neither the olfactomedin domain alone (OLF) nor an Fc-fusion containing the extracellular region of the gliomedin-related myocilin protein were able to bind heparin, indicating that the heparin-binding sequence in gliomedin is located outside its olfactomedin domain. Collectively, our results demonstrate that the incorporation of gliomedin to Schwann cell ECM is mediated by its binding to HSPGs.

![**Heparin-dependent binding of gliomedin to Schwann cells.** (A--D) Heparin inhibits the interaction of gliomedin with Schwann cells and Schwann cell ECM. Binding of an Fc-fusion protein containing the extracellular domain of gliomedin (ECD-Fc; red) to Schwann cells grown in the absence (A and B) or presence (C and D) of ascorbic acid. Schwann cell nuclei were labeled with DAPI (blue). Preincubation of the cells with heparin abolished the binding of ECD-Fc to both Schwann cells and the ECM (B and C). (E) Gliomedin is a heparin-binding protein. Medium containing the Fc-fusion proteins indicated on top was incubated with protein A--agarose (PA) or heparin--Sepharose beads (HS). Precipitated material was resolved on an SDS gel, followed by immunoblotting with an antibody to human Fc. An Fc-fusion protein of myocilin was used as a control. The location of molecular weight marker is shown on the right in kilodaltons. Bars, 30 μm.](jcb1770551f07){#fig7}

Discussion
==========

Gliomedin was isolated as a glial ligand for neurofascin and NrCAM, which are two immunoglobulin CAMs that associate with Na^+^ channels at the nodes of Ranvier ([@bib15]). It was shown that immunopatching the olfactomedin domain of gliomedin on DRG neurons induced the clustering of these two axonodal CAMs and the assembly of nodal-like clusters containing Na^+^ channels, ankyrin G, and βIV spectrin ([@bib15]). In the present work, we report that gliomedin shares several characteristics with collagenous transmembrane proteins that may account for its clustering activity. We demonstrate that the majority of gliomedin exists as a secreted protein, which forms multimers that are further incorporated into the Schwann cell ECM by binding to HSPGs ([Fig. 8](#fig8){ref-type="fig"}). We suggest that the entrapment of gliomedin within the perinodal space surrounding the Schwann cell microvilli creates an arrayed matrix of multiple binding sites for the axonodal CAMs that drives an efficient clustering of these CAMs on the axolemma.

![**A proposed model for the accumulation of gliomedin at nodes.** Gliomedin is synthesized in the ER (A), followed by trimerization of the collagen domain, which forms a triple helical configuration that subsequently appears on the plasma membrane (B). Cleavage of gliomedin trimers occurs at the cell surface by furin, releasing it to the medium (C). Cleavage of gliomedin may also occur at the trans-Golgi network (not depicted). (D) Secreted gliomedin accumulates at the perinodal space by binding to HSPGs, creating a local high concentration that interacts with and clusters the axonodal CAMs.](jcb1770551f08){#fig8}

Secreted forms of gliomedin
---------------------------

The domain architecture of gliomedin resembles that of collagenous transmembrane proteins, which are a growing group of type II transmembrane proteins that function as cell surface receptors and matrix components ([@bib16]; [@bib38]). Most of the collagenous transmembrane proteins are shed from the cell surface by furin or a furin-dependent proteolytic cleavage ([@bib16]). We found that medium conditioned by Schwann cells contained two soluble fragments of gliomedin, indicating that two distinct cleavage sites are present in its extracellular domain. Gliomedin contains four basic amino acids RNKR at position 91--94 between the transmembrane and collagen domains that match the consensus site for furin, which is a proprotein convertase that cleaves after the C-terminal arginine residue in the sequence R-X-K/R-R ([@bib51]). Mutating the two arginines at position 91 and 94, resulted in a marked reduction in the secretion of gliomedin to the medium, suggesting that, similar to other collagenous transmembrane proteins, gliomedin is processed by a furinlike enzyme. Immunolabeling rat sciatic nerves using antibodies to different regions of the molecule demonstrated that the transmembrane form of gliomedin is completely absent from nodes, indicating that the processing of gliomedin also occurs in vivo. The finding that only the cleaved form of gliomedin is present at nodes is further supported by previous immunoelectron microscopy data showing that gliomedin immunoreactivity was also present between the microvilli at the nodal gap ([@bib15]). At present, it is not clear whether the furin-dependent processing of gliomedin occurs in the trans-Golgi, at the cell surface, or at both sites, as was recently demonstrated for collagen XIII ([@bib53]).

The N-terminal sequence of the smaller gliomedin fragment found in the medium of transfected HEK-293 cells unequivocally identified as DDTLVG, demonstrating that the second cleavage of gliomedin occurs between asparagine 277 (N277) and aspartic acid 278, which is located N-terminal to the olfactomedin domain. This sequence corresponds well to the known cleavage site of the bone morphogenetic protein/Tolloid-like metalloproteinases, which process several collagens, as well as a variety of other ECM proteins ([@bib18]). However, it should be emphasized, that the major proteolytic product of gliomedin detected in Schwann cell medium was the 91-kD fragment containing both the collagen and the olfactomedin domains. In contrast, we detected only a small amount of the 45-kD olfactomedin fragment in Schwann cell media grown for long periods of time in culture, indicating that the second proteolytic cleavage is much less common. In support, we did not detect the 45-kD protein in the medium of astrocytes and we could not extract it from nerve lysates (unpublished data).

Multimers of gliomedin are required for its interaction with the axonodal CAMs
------------------------------------------------------------------------------

Previous experiments have demonstrated that the olfactomedin domain of gliomedin mediates its interaction with neurofascin or NrCAM ([@bib15]). We extend these findings and note an important difference between the ability of the olfactomedin domain to bind neurofascin as a single domain (OLF), or as part of the entire extracellular domain of gliomedin (ECD). We show that although ECD-Fc could bind to neurofascin as a soluble dimer (dimers are enforced by the Fc tag), binding of OLF-Fc required its multimerization with a secondary antibody. Thus, it appears that specific multimerization sequences outside the OLF domain are critical for the interaction between gliomedin and the axonodal CAMs. The extracellular region of gliomedin also includes a collagen-like domain, which contributes to the multimerization of gliomedin by forming triple helices ([@bib19]). Several experimental observations support this possibility. First, mass spectrometry analysis showed that the collagen domain of gliomedin is resistant to digestion by trypsin and chemotrypsin (unpublished data), which are a common characteristic of collagen triple helices ([@bib7]). Second, using a chemical cross-linker (BS^3^), we demonstrated that gliomedin is found as trimers in Schwann cells treated with ascorbate, which is known to stimulate prolylhydroxylation of collagens, which is required for the formation of intramolecular hydrogen bonds and stabilization of their triple helical conformation ([@bib52]). Furthermore, we also detected multimers of gliomedin, suggesting that the formed homotrimers may be further assembled into higher-order structures that are similar to various collagens ([@bib38]). Third, and in keeping with the latter possibility, we found that treatment of Schwann cells with ascorbic acid markedly reduced the solubility of gliomedin. Finally, we show that gliomedin undergoes self-association, which is mediated by the N-terminal region of the protein and is required for its interaction with the axonodal CAMs. Gliomedin contains a juxtamembrane α-helical, coiled-coil sequence at position R42-E61, which, in transmembrane collagens, directs correct chain association and initiates a zipperlike folding of the triple helix ([@bib28]; [@bib35]). Self-association of gliomedin was reduced by the deletion of this coiled-coil sequence, but was almost completely abolished when the entire N-terminal domain was deleted. This result indicates that although the juxtamembrane coiled-coil sequence may facilitate trimerization, adjacent noncollagenous sequences within the N-terminal domain are required for the recognition and association of gliomedin monomers. In keeping with such a role, we found that binding of a soluble extracellular region of gliomedin lacking the N-terminal domain (ECDdNTR-Fc) to neurofascin required its multimerization.

Incorporation of gliomedin into Schwann cell ECM
------------------------------------------------

Previous immunofluorescence and immunoelectron microscopy analyses of peripheral nerves demonstrated that gliomedin is localized to the nodes of Ranvier ([@bib15]). The finding that gliomedin is a secreted protein, thus, poses an important question as to how it is concentrated at the nodal gap. Binding experiments using mixed Schwann cells/neuron cultures showed that a secreted extracellular domain of gliomedin binds to both cell types. Although the olfactomedin domain mediated its binding to neurons, the N-terminal and collagen domains of gliomedin were required for its interaction with Schwann cells, suggesting the existence of another ligand for gliomedin at the perinodal space. Using isolated rat Schwann cells, we demonstrated that the extracellular domain of gliomedin binds to Schwann cell ECM. Moreover, we found that endogenous gliomedin secreted from Schwann cells was incorporated into fibrillar matrix deposits that were labeled for collagen V, laminin, and perlecan. We also showed that a soluble extracellular domain of neurofascin strongly bound to these matrix deposits, indicating that the embedding of gliomedin within the ECM does not diminish its ability to interact with the axonodal CAMs. These results suggest that gliomedin is a specific component of the Schwann cell perinodal matrix, which was originally described by Ranvier as the cement disc ([@bib27]). This conclusion is further supported by the recent identification of gliomedin as an ECM protein synthesized by follicular papilla, which is a group of specialized mesenchymal cells in the hair follicle ([@bib8]). It is also of interest to note that all of the known olfactomedin-containing proteins have been identified as ECM proteins ([@bib49]; [@bib4]; [@bib55]; [@bib22]; [@bib57]; [@bib1]; [@bib17]), which, similarly to gliomedin, have restricted tissue distributions and thus may comprise a unique subgroup of ECM elements as recently suggested ([@bib30]).

The accurate deposition of many ECM proteins is often regulated by their binding to HSPGs ([@bib6]). We showed that the binding of exogenous gliomedin to Schwann cells was inhibited by heparin, suggesting that it binds HSPGs. In agreement, incubation of ascorbate-treated Schwann cells with heparin completely removed gliomedin from the ECM. We also showed that the extracellular domain of gliomedin directly bound to heparin--Sepharose through its collagen domain. Consistent with this observation are two putative heparin-binding sequences located in the collagen-like domain of gliomedin (amino acid positions 176 and 253), both composed of a BBXB motif (where B represents a basic residue). Several HSPGs were shown to be expressed by Schwann cells, including syndecans ([@bib9]), perlecan and glypican ([@bib43]), agrin ([@bib54]), and collagen XVIII ([@bib21]), of which only syndecans were shown to be present at the nodes of Ranvier ([@bib20]; [@bib37]). Whether gliomedin interacts with any of these HSPGs, and whether such interaction is important for its localization at nascent nodes, is of great interest and will be determined in future studies.

Implications on nodes formation
-------------------------------

The accumulation of Na^+^ channels at the nodes of Ranvier in the PNS depends on the presence of myelinating Schwann cells and requires the interaction of these channels with NrCAM and neurofascin, as well as with βIV spectrin and the cytoskeletal adaptor protein ankyrin G ([@bib24]; [@bib5]; [@bib33]; [@bib42]; [@bib23]; [@bib11]; [@bib29]; [@bib48]). It was previously suggested that these channels are being recruited by ankyrin G to the axonodal CAMs, which were first clustered by gliomedin present on glial processes that contact the nodal axolemma ([@bib15]; [@bib46]). Based on our current results demonstrating that gliomedin is a secreted protein, one should consider a modification of this model. Thus, we propose that during the development of peripheral nerves, gliomedin is released from the cell surface by proteolytic cleavage and is then entrapped at the edges of myelinating Schwann cells by HSPGs that are enriched at these sites. Binding of gliomedin to HSPGs may serve two purposes. First, it would allow the buildup of a tremendously high local concentration of gliomedin at the nodal gap, and second, it would create a meshlike array of gliomedin that would facilitate high avidity binding and further clustering of neurofascin and NrCAM present on the axolemma. Heparan sulfate glycosaminoglycan residue could be provided by transmembrane syndecans that are present on microvilli processes, as well as by secreted HSPGs that are found at the basal lamina overlaying the nodal gap. In keeping with the latter possibility, it has recently been demonstrated that the composition of the basal lamina at the nodes is different from that of the internodal region and contains specific ECM components, such as laminin α5β1γ2 ([@bib39]). Alternatively, gliomedin may interact with secreted HSPGs, such as perlecan, which would be immobilized at the nodal gap by dystroglycan that is present on the Schwann cell microvilli and is required for the normal clustering of nodal Na^+^ channels ([@bib44]; [@bib39]). Once accumulated at the nascent nodes, gliomedin multimers would avidly bind to and induce the clustering of the axonodal CAMs, thereby facilitating the assembly of nodal complexes containing Na^+^ channels.

Materials and methods
=====================

Tissue culture methods
----------------------

Dissociated rat DRG cultures were grown in Neurobasal medium (Invitrogen) supplemented with B27 (Invitrogen) and 50 ng/ml NGF (Neurobasal medium; Alomone Labs) for 5 d before being used in binding experiments. Purified DRG neurons were established by treating dissociated mixed cultures with two cycles (2 d each) of NB medium containing 10 μM uridine/10 μM 5′-Fluoro 2′-deoxyuridine (Sigma-Aldrich) to eliminate fibroblasts and Schwann cells. Schwann cells isolated from P4 rat sciatic nerve were grown in Schwann cell proliferation medium (DME, 3% FBS, 10% NDFβ conditioned medium, 2 μM forskolin, 2 mM glutamine, and 1 mM pyruvate) on primaria culture dishes (Falcon). To stimulate ECM assembly, Schwann cells were treated with 50 μg/ml L-ascorbic acid (Sigma-Aldrich) for 48 h. To remove cells from the culture dish, cultures were treated with PBS + 0.5% Triton X-100 and 20 mM ammonium hydroxide for 10 s and subsequently washed with PBS.

Constructs, recombinant proteins, and antibodies
------------------------------------------------

Gliomedin Fc fusions COL-Fc (residues 49--294), OLF-Fc (residues 288--543), ECD-Fc (residues 49--543), and NF155-Fc were previously described ([@bib15]). Fc fusions ECDdNTR-Fc and ECDdCC-Fc (residues 139--543 and 62--543, respectively) were generated by cloning the corresponding cDNA to pSX-Fc. Myocilin-Fc was generated by cloning full-length myocilin amplified by PCR from rat Schwann cell cDNA into pCX-Fc. Generation of the mutant proteins gliomedin R91G and R94A was done using the 5′ primers CCCATGAGTGCAGCCGGCAATAAGCGAGC (for R91G, NaeI site was inserted), and GCAGCGCGCAATAAGGCTAGCCACGGCGGCGAG (for R94A, NheI site was inserted) and their complementary 3′ primers. PCR was performed using Pfu DNA Polymerase (Promega) on pRKpF10 ([@bib15]) as a template, followed by a DpnI digestion.

Polyclonal and monoclonal antibodies to gliomedin (Ab720 and mAb94) were previously described ([@bib15]). Polyclonal antibody 320 was generated by immunizing rabbits with the aforementioned purified recombinant protein OLF-Fc. Polyclonal antibody 836 was generated against a synthetic peptide corresponding to residues 1--16 that comprise the cytoplasmic tail of gliomedin. Polyclonal antibodies to α4(V) and to α1(V) were obtained from David Carey. Rabbit anti--laminin antibody was purchased from Sigma-Aldrich.

Fc-binding and immunofluorescence
---------------------------------

Cells were grown on poly-L-lysine--coated (Sigma-Aldrich) coverslips. For binding experiments, conditioned media containing various Fc-fusions were either mixed with a Cy3-conjugated anti--human Fc antibody for 30 min before the binding procedure or were not mixed ("nonclustered"). After a 30-min incubation of the cells with the conditioned media at RT, cells were washed and fixed with 4% PFA for 5 min at RT. In the case of nonclustered binding, coverslips were incubated with a Cy3-conjugated anti--human Fc antibody after fixation for 30 min at RT. For antibody labeling, cells were fixed in 4% PFA, washed with PBS, and incubated in blocking solution (PBS, 10% normal goat serum, 0.1% Triton X-100, 1% glycine) for 30 min. Primary antibodies diluted in blocking solution were added for 1 h at RT, followed by washing with PBS and incubation with secondary antibodies diluted in blocking solution for 40 min. Coverslips were then washed, mounted in elvanol, and analyzed on a microscope (Eclipse E1000; Nikon; objectives 20×/0.5 NA, 40×/1.3 NA, and 60×/1.4 NA) equipped with a camera (ORCA-ER; Hamamatsu). Fluorescence images were acquired using Openlab software (Improvision) and figures were mounted using Photoshop software (Adobe). In the case of laminin and collagen V staining, live cultures were incubated with primary antibodies for 45 min, followed by washing and fixing. Secondary antibodies were added after a 30-min blocking as described for nonclustered cells. To assess the effect of heparin on the gliomedin labeling, Fc fusion binding or antibody labeling were performed after a 30-min treatment with 10 μg/ml heparin in PBS supplemented with Ca^2+^ and Mg^2+^. Teased sciatic nerves were prepared and immunolabeled as previously described ([@bib15]).

Immunoprecipitation, pull-down, and immunoblot analysis
-------------------------------------------------------

For immunoprecipitation, Schwann cells or transfected cell conditioned media and cell extracts (lysed in 50 mM Hepes, pH 7.2, 150 mM NaCl, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 2 mM PMSF, and 10 μM aprotinin and leupeptin) were immunoprecipitated by polyclonal anti-gliomedin antibodies cross-linked to protein A--Sepharose beads using Dimethyl Pimelimidate (Sigma-Aldrich). Samples were analyzed by electrophoresis on 10% polyacrylamide SDS gels. For cross-linking experiments, Schwann cells were treated with BS^3^ (Pierce Chemical Co.) according to manufacturer\'s protocol before cell lysis. Cell extracts were subjected to the aforementioned immunoprecipitation. To asses the solubility of gliomedin after ascorbate treatment, immunoprecipitation was performed in an SDS-free RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, 1 mM EDTA, 2 mM PMSF, and protease inhibitors) or in a RIPA buffer containing 0.1% SDS. For pull-down experiments, protein A beads bound with various gliomedin Fc-fusion proteins were mixed with cell extracts of HEK-293T cells transfected with either gliomedin-myc or PSD93-myc as control, for 4 h at 4°C. Beads were subsequently washed and analyzed by electrophoresis and immunoblot using anti-myc antibodies. For heparin pull-down experiments, conditioned media of various gliomedin Fc-fusion proteins and myocilin-Fc were mixed with either protein A--Sepharose or heparin--Sepharose beads for 1 h at RT. Beads were subsequently washed and resolved by electrophoresis and immunoblot using anti--human antibodies. N-terminal sequencing of a secreted Fc-tagged gliomedin was determined using Procise 491 protein sequencer (Applied Biosystems).
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